LB Pharmaceuticals SEC Filings

LB Pharmaceuticals Inc. (LBRX)no securities beneficially owned in LB Pharmaceuticals. This establishes that the executive currently holds no direct or indirect ownership in the company’s securities under the relevant reporting rules.

LB Pharmaceuticals (LBRX) amended its headquarters lease to add 4,634 rentable square feet on the 10th floor at One Penn Plaza, New York. The underlying lease term remains scheduled to expire on March 31, 2032.

The landlord shall endeavor to deliver the Expansion Premises on or prior to July 1, 2026. From the Expansion Premises Commencement Date, fixed rent for the added space will be $430,962 per year for the first three years, increasing to $477,302 per year on the third anniversary. The parties agreed to a fixed rent abatement for the first 150 days after commencement, as set forth in the amendment.

LB Pharmaceuticals (LBRX) appointed Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, and announced the move via a press release. The company also plans to grant her an equity award as an inducement to join, made outside of—but subject to—the 2025 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). A copy of the press release is filed as Exhibit 99.1.

LB Pharmaceuticals (LBRX) reported Q3 2025 results highlighted by its September IPO and a much stronger balance sheet. The company posted a Q3 net loss of $3.6 million, a significant improvement from $14.2 million a year ago, as research and development ($2.4 million) and general and administrative ($2.8 million) expenses were lower.

The IPO closed on September 12, issuing 21,850,000 shares at $15.00 for $327.8 million gross and $302.3 million net. All preferred shares converted into 3,191,334 common shares immediately prior to closing, following a 1‑for‑27.8874 reverse stock split on September 8. As of September 30, cash and cash equivalents were $269.7 million and marketable securities were $44.7 million, bringing cash and securities to $314.5 million. Management states these resources fund operations for at least twelve months from issuance of the statements.

Total assets were $320.7 million against liabilities of $10.5 million, with stockholders’ equity of $310.2 million. The derivative warrant liability decreased to $0.9 million. 25,299,102 common shares were outstanding as of November 6, 2025. The company’s lead candidate, LB‑102, is described as Phase 3‑ready for acute schizophrenia.

LB Pharmaceuticals (LBRX) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 via an 8-K.

The disclosure under Item 2.02 is expressly stated as “furnished,” not “filed,” which limits its application under Section 18 of the Exchange Act. The filing lists the company’s common stock on The Nasdaq Stock Market under the symbol LBRX, and is signed by Chief Executive Officer Heather Turner.

Marc Panoff, Senior Vice President, Finance of LB Pharmaceuticals, Inc. (LBRX), reported changes to his option holdings on September 10, 2025. The filing shows a one-time option repricing that reduced the exercise price of multiple employee stock options to $15, which the company notes is the issuer's initial public offering price. The report lists several option awards affected: 3,944; 896; 1,255; 14,343; 7,171; and 90,525 shares, with some portions immediately exercisable and others subject to standard vesting schedules. Vesting details are provided for each award and the form is signed by Mr. Panoff on September 12, 2025.

Marc L. Panoff, Senior Vice President, Finance and director of LB Pharmaceuticals (LBRX), filed an Initial Statement of Beneficial Ownership reporting direct ownership of 10,242 shares of common stock and multiple employee stock options. The filing lists options exercisable between 2028 and 2034 covering 27,609 underlying shares with exercise prices ranging from $41.84 to $69.72. The form is signed and dated 09/10/2025.

Pontifax entities and two individual managing partners report ownership of 1,411,681 shares of LB Pharmaceuticals Inc. common stock, representing 6.3% of the outstanding shares. The holdings arise from a prior $15,000,000 purchase of Series C preferred stock that converted into 411,681 common shares upon the issuer's IPO, plus additional purchases by Pontifax (Cayman) and Pontifax (Israel) of 363,737 and 626,263 common shares, respectively, in the IPO at $15.00 per share. The reporting group states the securities were acquired for investment purposes and may review, discuss or transact in the securities over time. One Reporting Person, Ran Nussbaum, serves on the issuer's board and may influence corporate matters. The filing otherwise discloses no recent transactions in the past 60 days and no relevant legal proceedings.

RA Capital and affiliated persons reported ownership of 1,675,000 shares, representing 7.5% of LB PHARMACEUTICALS INC (ticker LBRX) common stock as of September 12, 2025. The holdings are reported across RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals, Peter Kolchinsky and Rajeev Shah, each shown with shared voting and dispositive power over the 1,675,000 shares and no sole voting or dispositive power. The filing states the Fund holds the shares directly, RA Capital serves as the Fund’s investment adviser with delegated voting and disposition authority, and the Reporting Persons expressly disclaim that they form a "group." The 7.5% figure is calculated using 22,442,989 shares outstanding disclosed in the issuer’s September 10, 2025 prospectus.